Tirzepatide Delivers Sweeping Cardiometabolic Benefits Beyond Weight Loss

Cardiovascular disease remains the leading cause of death globally, responsible for roughly one-third of all deaths in 2019, with a direct and indirect U.S. economic burden exceeding $422 billion annually. Against this backdrop, the emergence of incretin-based therapies with demonstrated cardiometabolic effects has generated enormous clinical interest. This review by Sattar and colleagues at the University of Glasgow and Eli Lilly synthesizes the current body of evidence on tirzepatide's effects across multiple cardiometabolic domains, drawing on phase 2 and phase 3 randomized controlled trial data from the SURPASS and SURMOUNT programs.

Tirzepatide is a once-weekly subcutaneous injection that acts as a dual agonist at both GIP and GLP-1 receptors, providing synergistic or additive effects on glucose-dependent insulin secretion, glucagon suppression, gastric emptying delay, and appetite regulation. In the landmark SURMOUNT-1 phase 3 trial (people with obesity or overweight without T2D, 72 weeks), tirzepatide produced significant placebo-adjusted improvements in systolic blood pressure, diastolic blood pressure, triglycerides, and waist circumference. Consistent benefits in SBP, DBP, HDL-C, LDL-C, and triglycerides were replicated across SURMOUNT-3, SURMOUNT-4, and SURMOUNT-2 (the T2D obesity cohort), establishing a robust and reproducible lipid and blood pressure profile across populations.

Body composition data from a SURMOUNT-1 DEXA sub-study revealed that mean total body fat mass decreased by 33.9% with tirzepatide versus 8.2% with placebo (estimated treatment difference: −25.7%; 95% CI: −31.4 to −20.0). The fat-to-lean mass ratio fell from 0.93 to 0.70 with tirzepatide versus 0.95 to 0.88 with placebo, indicating meaningful improvement in body composition beyond mere weight loss. MRI data from the SURPASS-3 sub-study in T2D patients showed tirzepatide reduced liver fat content by a placebo-adjusted 4.71% (p<0.0001) versus insulin degludec, while also significantly reducing visceral adipose tissue and abdominal subcutaneous adipose tissue volumes — parameters that increased with insulin degludec.

Renal outcomes data, while still preliminary and largely post hoc, are particularly noteworthy. Pooled analysis of SURPASS 1–5 showed a clinically meaningful decrease in urine albumin-to-creatinine ratio (UACR) with tirzepatide versus comparators, and a SURMOUNT-2 post hoc analysis confirmed reduced albuminuria without adverse eGFR effects in T2D patients with preserved baseline kidney function. The dedicated TREASURE-CKD trial (NCT05536804) will prospectively evaluate tirzepatide's effects on kidney oxygenation, inflammation, fibrosis, and renal blood flow in CKD patients with or without T2D.

Perhaps the most striking finding concerns diabetes prevention. In the 3-year SURMOUNT-1 extension in adults with prediabetes and obesity, tirzepatide 15 mg achieved approximately 20% average body weight reduction sustained over 3 years, with a 94% reduction in risk of T2D progression versus placebo (hazard ratio: 0.07; 95% CI: 0.03–0.17). A validated ASCVD risk engine applied post hoc to SURMOUNT-1 data found tirzepatide-treated participants had a predicted 10-year ASCVD risk reduction of 16.4%–23.5% from baseline versus a 12.7% increase in the placebo group, with tirzepatide users showing 2.4x greater odds (95% CI: 1.7–3.5; p<0.001) of improved ASCVD risk profiles. Hard cardiovascular outcome data from SURPASS-CVOT (T2D) and SURMOUNT-MMO (obesity without T2D) are eagerly awaited to confirm whether these surrogate improvements translate to reduced MACE events.